THRX — Theseus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $181.72m
- -$23.40m
- 42
- 36
- 15
- 21
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 4.94 | 6.84 | 27.3 | 54.1 |
Operating Profit | -4.94 | -6.84 | -27.3 | -54.1 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -7.18 | -12 | -27.3 | -50.6 |
Net Income After Taxes | -7.18 | -12 | -27.3 | -50.6 |
Net Income Before Extraordinary Items | ||||
Net Income | -7.18 | -12 | -27.3 | -50.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -7.18 | -12 | -27.3 | -50.6 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.191 | -0.32 | -0.706 | -1.31 |
Dividends per Share |